These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32374879)

  • 1. FVIII half-life extension by coadministration of a D'D3 albumin fusion protein in mice, rabbits, rats, and monkeys.
    Pestel S; Beltz HW; Claar P; Lind H; Mischnik M; Raquet E; Andrews A; Simmonds J; Tomasetig V; Dower SK; Tjärnlund-Wolf A; Schulte S; Schmidt PM; Weimer T
    Blood Adv; 2020 May; 4(9):1870-1880. PubMed ID: 32374879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased potency of recombinant VWF D'D3 albumin fusion proteins engineered for enhanced affinity for coagulation factor VIII.
    Chia J; Pestel S; Glauser I; Emmrich K; Hardy MP; Mischnik M; Raquet E; Tomasetig V; Claar P; Zalewski A; Bass GT; Turnbull V; Chen CG; Wilson MJ; Panousis C; Weimer T; Andrews A; Verhagen AM; Dower SK
    J Thromb Haemost; 2021 Nov; 19(11):2710-2725. PubMed ID: 34333849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
    Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis.
    Guillet B; Hassoun A; Wibaut B; Harroche A; Biron-Andréani C; Repesse Y; d'Oiron R; Tardy B; Pan Petesch B; Chamouni P; Gay V; Fouassier M; Pouplard C; Martin C; Catovic H; Delavenne X
    Thromb Haemost; 2023 May; 123(5):490-500. PubMed ID: 36758611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
    Stasyshyn O; Djambas Khayat C; Iosava G; Ong J; Abdul Karim F; Fischer K; Veldman A; Blackman N; St Ledger K; Pabinger I
    J Thromb Haemost; 2017 Apr; 15(4):636-644. PubMed ID: 28166608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.
    Klamroth R; Simpson M; von Depka-Prondzinski M; Gill JC; Morfini M; Powell JS; Santagostino E; Davis J; Huth-Kühne A; Leissinger C; Neumeister P; Bensen-Kennedy D; Feussner A; Limsakun T; Zhou M; Veldman A; St Ledger K; Blackman N; Pabinger I
    Haemophilia; 2016 Sep; 22(5):730-8. PubMed ID: 27434619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
    Mahlangu J; Kuliczkowski K; Karim FA; Stasyshyn O; Kosinova MV; Lepatan LM; Skotnicki A; Boggio LN; Klamroth R; Oldenburg J; Hellmann A; Santagostino E; Baker RI; Fischer K; Gill JC; P'Ng S; Chowdary P; Escobar MA; Khayat CD; Rusen L; Bensen-Kennedy D; Blackman N; Limsakun T; Veldman A; St Ledger K; Pabinger I;
    Blood; 2016 Aug; 128(5):630-7. PubMed ID: 27330001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.
    Yee A; Gildersleeve RD; Gu S; Kretz CA; McGee BM; Carr KM; Pipe SW; Ginsburg D
    Blood; 2014 Jul; 124(3):445-52. PubMed ID: 24850761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
    Schmidbauer S; Witzel R; Robbel L; Sebastian P; Grammel N; Metzner HJ; Schulte S
    Thromb Res; 2015 Aug; 136(2):388-95. PubMed ID: 26037285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The story of a unique molecule in hemophilia A: recombinant single-chain factor VIII.
    Pabinger-Fasching I
    Thromb Res; 2016 May; 141 Suppl 3():S2-4. PubMed ID: 27288063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
    Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
    Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
    Pipe SW; Montgomery RR; Pratt KP; Lenting PJ; Lillicrap D
    Blood; 2016 Oct; 128(16):2007-2016. PubMed ID: 27587878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lonoctocog alfa (rVIII-SingleChain) for the treatment of haemophilia A.
    Raso S; Hermans C
    Expert Opin Biol Ther; 2018 Jan; 18(1):87-94. PubMed ID: 29256333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
    Olivieri M; Simpson M; Yan S; Fedorovsky J; Zhang X; Tomic R; Pinachyan K; Mancuso ME
    Curr Med Res Opin; 2022 Jul; 38(7):1133-1139. PubMed ID: 35387548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany.
    Olivieri M; Sommerer P; Maro G; Yan S
    Eur J Haematol; 2020 Apr; 104(4):310-317. PubMed ID: 31883398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
    Zollner S; Schuermann D; Raquet E; Mueller-Cohrs J; Weimer T; Pragst I; Dickneite G; Schulte S
    J Thromb Haemost; 2014 Feb; 12(2):220-8. PubMed ID: 24641308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching hemophilia A patients to rVIII-SingleChain: The Iberian experience.
    Calvo-Villas JM; Núñez-Vázquez R; Benítez-Hidalgo O; García-Díaz C; Galmés B; Carvalho M; Serrano-Torres P; Aznar-Salatti J; Álvarez-Román MT
    Medicine (Baltimore); 2024 Sep; 103(36):e39255. PubMed ID: 39252288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians.
    Borchiellini A; Castaman G; Feola G; Ferretti A; Giordano P; Luciani M; Malcangi G; Margaglione M; Molinari AC; Pollio B; Rocino A; Santoro C; Schiavulli M; Zanon E
    J Thromb Thrombolysis; 2022 May; 53(4):934-944. PubMed ID: 34775566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.